GILD Stock Analysis — Gilead Sciences
Sector: Healthcare
AI Verdict
Gilead trades at 31.1x next year's earnings while analysts expect a 41.2% drop in EPS, so you're paying a premium the numbers don't yet support unless its antiviral drug moat delivers a surprise pipeline win.
Competitive Moat
Gilead Sciences holds a defensible position in antiviral therapies, especially for HIV and hepatitis C, thanks to a portfolio of patented drugs and decades of clinical trial data. The company's moat relies on regulatory exclusivity and the complexity of developing rival treatments in these therapeutic areas.
Summary
Gilead's sharp expected earnings drop is at odds with its premium forward valuation.
Where It Stands
Gilead is up 24.08% over the past year, trades at 31.1x next year's earnings (well above the healthcare sector median of 22x), and its RSI of 62.5 signals a neutral-to-elevated zone.
Key Metrics
- RSI: 62.5 — Near Overbought
- Trailing P/E: 18.3x
- Forward P/E: 31.1x
- Earnings Growth: -0.4%
- Revenue Growth: +0.0%
- Market Cap: $166.7B
- Dividend Yield: 0.02%
- 1-Year Return: 24.08%
- 52-Week High: $157.29
- 52-Week Low: $107.75
Analyst Consensus
30 Buy · 7 Hold · 0 Sell (37 analysts)
Bull Case
The trailing P/E of 18.3x is below the sector median, suggesting the market still values its core HIV and antiviral franchises after a 24.08% 1-year return.
Bear Case
With forward EPS expected to fall by 41.2% and the forward P/E jumping to 31.1x, a return to sector-average multiples would mean a 29% drop from here if earnings don't recover.
Catalyst to Watch
Watch for clinical trial readouts or regulatory decisions on pipeline drugs, as positive results could justify the high multiple despite the projected earnings decline.